Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Related party transactions

v3.22.1
Related party transactions
12 Months Ended
Dec. 31, 2021
Disclosure of transactions between related parties [abstract]  
Related party transactions

 

20. Related party transactions

 

The directors and senior executives who have the authority and responsibility for planning, directing and controlling the entity are considered to be key management personnel. Total remuneration in respect of these individuals is disclosed in the table below:

 

    2021     2020     2019  
    £     £     £  
                   
Short-term employee benefits     1,061,325       982,027       688,325  
Share-based payments             287,444       444,941  
Related party transactions     1,061,325       1,269,471       1,133,266  

 

During the years ended December 31, 2020 and 2021, the Group made purchases of cell culture media from Cell Science & Technology Institute, Inc., a company in which significant shareholder NIPRO Corporation (Osaka, Japan), has a significant interest in the amount of £30,775 and £52,795 respectively.

 

During the years ended December 31, 2020 and 2021, the Group used consultancy services from Theraldia Consulting Limited a company in which Dr Alan Clark has a significant interest in the amount of £22,621 and £Nil respectively.

 

During the year ended December 31, 2020, the executive directors agreed to defer a proportion of their compensation. Repayment of deferred compensation would be initiated on receipt of an agreed level of funding to support the future capital requirements of the business and settlement would be staged over twelve months. As at December 31, 2021 the balance outstanding to executive directors totaled £591,886 (2020: £253,338).